These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24356563)

  • 21. High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer.
    Aparicio T; Schischmanoff O; Poupardin C; Mary F; Soufir N; Barrat C; Bellaiche G; Boubaya M; Choudat L; Cucherousset J; DesGuetz G; Wind P; Benamouzig R
    J Geriatr Oncol; 2014 Oct; 5(4):384-8. PubMed ID: 25176643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surface microstructures are associated with mutational intratumoral heterogeneity in colorectal tumors.
    Harada T; Yamamoto E; Yamano HO; Aoki H; Matsushita HO; Yoshikawa K; Takagi R; Harada E; Tanaka Y; Yoshida Y; Eizuka M; Yorozu A; Sudo G; Kitajima H; Niinuma T; Kai M; Sasaki Y; Tokino T; Sugai T; Nakase H; Suzuki H
    J Gastroenterol; 2018 Dec; 53(12):1241-1252. PubMed ID: 29948303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations.
    Correa GT; Bernardes VF; de Sousa SF; Diniz MG; Salles JM; Souza RP; De-Paula AM; Gomez RS; Gomes CC
    Tumour Biol; 2015 Nov; 36(11):9059-66. PubMed ID: 26084614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
    Rao B; Gao Y; Huang J; Gao X; Fu X; Huang M; Yao J; Wang J; Li W; Zhang J; Liu H; Wang L; Wang J
    Int J Colorectal Dis; 2011 May; 26(5):593-601. PubMed ID: 21404058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer.
    Jesinghaus M; Wolf T; Pfarr N; Muckenhuber A; Ahadova A; Warth A; Goeppert B; Sers C; Kloor M; Endris V; Stenzinger A; Weichert W
    Am J Surg Pathol; 2015 Aug; 39(8):1140-7. PubMed ID: 25786087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
    Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
    PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
    BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The presence of telomere fusion in sporadic colon cancer independently of disease stage, TP53/KRAS mutation status, mean telomere length, and telomerase activity.
    Tanaka H; Beam MJ; Caruana K
    Neoplasia; 2014 Oct; 16(10):814-23. PubMed ID: 25379018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three cases of rare salivary gland tumours: a molecular study of TP53, CDKN2A/ARF, RAS, BRAF, PTEN, MAPK2 and EGFR genes.
    Falbo V; Floridia G; Censi F; Marra M; Foschini MP; Taruscio D
    Oncol Rep; 2011 Jul; 26(1):3-11. PubMed ID: 21503581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions of multiple gene alterations in colorectal liver metastases.
    Kawaguchi Y; Velasco JD; Arvide EM; Wei SH; Vauthey JN
    Chin Clin Oncol; 2019 Oct; 8(5):50. PubMed ID: 31500427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical Role of p53 and K-ras in the Diagnosis of Early Colorectal Cancer: a One-year, Single-center Analysis.
    Lu HY; Lin RT; Zhou GX; Yu TM; Liu ZJ
    Int J Med Sci; 2017; 14(11):1154-1162. PubMed ID: 29104470
    [No Abstract]   [Full Text] [Related]  

  • 32. Colorectal cancer risk and patients' survival: influence of polymorphisms in genes somatically mutated in colorectal tumors.
    Huhn S; Bevier M; Pardini B; Naccarati A; Vodickova L; Novotny J; Vodicka P; Hemminki K; Försti A
    Cancer Causes Control; 2014 Jun; 25(6):759-69. PubMed ID: 24706189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological Features and Predictive Factors for Colorectal Cancer Outcome in the Kingdom of Saudi Arabia.
    Aldiab A; Al Khayal KA; Al Obaid OA; Alsheikh A; Alsaleh K; Shahid M; Alkharji H
    Oncology; 2017; 92(2):75-86. PubMed ID: 27915339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human germline and somatic cells have similar TP53 and Kirsten-RAS gene single base mutation frequencies.
    Cole DN; Carlson JA; Wilson VL
    Environ Mol Mutagen; 2008 Jul; 49(6):417-25. PubMed ID: 18418864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis.
    Baviskar T; Momin M; Liu J; Guo B; Bhatt L
    Curr Drug Targets; 2021; 22(7):722-733. PubMed ID: 33213339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.
    Iacopetta B; Russo A; Bazan V; Dardanoni G; Gebbia N; Soussi T; Kerr D; Elsaleh H; Soong R; Kandioler D; Janschek E; Kappel S; Lung M; Leung CS; Ko JM; Yuen S; Ho J; Leung SY; Crapez E; Duffour J; Ychou M; Leahy DT; O'Donoghue DP; Agnese V; Cascio S; Di Fede G; Chieco-Bianchi L; Bertorelle R; Belluco C; Giaretti W; Castagnola P; Ricevuto E; Ficorella C; Bosari S; Arizzi CD; Miyaki M; Onda M; Kampman E; Diergaarde B; Royds J; Lothe RA; Diep CB; Meling GI; Ostrowski J; Trzeciak L; Guzinska-Ustymowicz K; Zalewski B; Capellá GM; Moreno V; Peinado MA; Lönnroth C; Lundholm K; Sun XF; Jansson A; Bouzourene H; Hsieh LL; Tang R; Smith DR; Allen-Mersh TG; Khan ZA; Shorthouse AJ; Silverman ML; Kato S; Ishioka C;
    Ann Oncol; 2006 May; 17(5):842-7. PubMed ID: 16524972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
    Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
    Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mathematical modeling the order of driver gene mutations in colorectal cancer.
    Li L; Hu Y; Xu Y; Tang S
    PLoS Comput Biol; 2023 Jun; 19(6):e1011225. PubMed ID: 37368936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.
    Raghav K; Shen JP; Jácome AA; Guerra JL; Scally CP; Taggart MW; Foo WC; Matamoros A; Shaw KR; Fournier K; Overman MJ; Eng C
    Br J Cancer; 2020 Oct; 123(8):1262-1270. PubMed ID: 32733093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
    Hasbullah HH; Musa M
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.